Our results showed that VPA enhanced the anticancer effects of AA by upregulating SVCT2 expression, resulting in increased AA uptake, ROS generation, and apoptotic cells in low-SVCT2-expressing colorectal cancer, HCT-116 and DLD-1, compared with AA treatment alone (without VPA). Here, SLC23A2 is linked to colorectal cancer.